Table 1 Comparison of patient baseline characteristics in the IGRT and non-IGRT groups
From: Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy
T stage | IGRT | Non-IGRT | P value |
|---|---|---|---|
1 | 78(30%) | 9(35%) | |
2 | 137(52%) | 13(50%) | |
3a | 40(15%) | 3(12%) | |
3b | 6(2%) | 0(0%) | |
4 | 0(0%) | 1(4%) | |
Not available | 4(1%) | 0 | |
Total | 265 | 26 | 0.8987 |
Gleason | |||
≤ 6 | 61(23%) | 9(35%) | |
7 | 147(55%) | 11(42%) | |
8 | 31(12%) | 2(8%) | |
9 | 21(8%) | 3(12%) | |
10 | 1(0.4%) | 1(4%) | |
Not available | 4(1%) | 0 | |
Total | 265 | 26 | 0.5782 |
PSA (ng/ml) | |||
< 4 | 13(5%) | 0(0%) | |
4-10 | 126(48%) | 14(54%) | |
10.1-20 | 85(32%) | 8(31%) | |
> 20 | 37(14%) | 4(15%) | |
Not available | 4(1%) | 0 | |
Total | 265 | 26 | 0.661 |
Prior TURP | 56 (21%) | 6 (23%) | 0.8043 |
Neoadjuvant LHRH agonist | 131 (50%) | 11 (42%) | 0.5407 |
Diabetes | 61 (23%) | 4 (15%) | 0.4656 |
Hypertension | 145 (55%) | 13 (50%) | 0.6827 |